Key facts
- Prescribe Life’s last known valuation is $3.7M (Jan 2026).
- It has raised $380K; the latest was Early Stage VC ($380K) in Jan 2026.
- Notable investors include Arya Ventures (North America).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Prescribe Life
- ·The full record, as it builds
Funding rounds
No funding rounds for Prescribe Life are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Prescribe Life
Developer of artificial intelligence-based performance tracking infrastructure designed to monitor resilience and support leadership development. The company's platform captures physiological and behavioral data, integrates wearable inputs, applies artificial intelligence to analyze recovery and resilience patterns, and provides real-time insights through dashboards and mobile applications, enabling coaches and corporate programs to identify burnout risks, personalize strategies, improve decision-making, and enhance long-term performance outcomes with evidence-based monitoring.
- Sector
- Information Technology
- HQ
- London, United Kingdom
- Founded
- 2023
- Website
- prescribelife.ai/
- Ownership
- Privately Held (backing)
Prescribe Life doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prescribe Life shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prescribe Life in its N-PORT filings yet. We sweep new filings monthly.